Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells

Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven...

Authors:
Van der Most, R. G., Currie, A. J., Mahendran, S., Prosser, A., Darabi, A., Robinson, B. W., Nowak, A. K., Lake, R. A

Authors notes:
Cancer Immunol Immunother (2009) 58 8 1219-28

Keywords:
tumor eradication, cyclophosphamide, concurrent depletion of regulatory T cells, a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

Abstract:
Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression, e.g., through CD25+ regulatory T cells. We addressed this question in a mouse model of mesothelioma by depleting or reconstituting CD25+ regulatory T cells in combination with two different chemotherapeutic drugs.